Welcome to Xbrane’s Capital Markets Day, including a unique visit to the new research lab, on September 22, 2022

Corporate Information

English

News

Other Corporate Information

Stockholm, Sweden – Xbrane (Nasdaq: XBRANE), Xbrane Biopharma AB invites analysts, investors and the media to its Capital Markets Day on September 22, 2022

The Capital Markets Day will be held in the Nils Ringertz hall, Biomedicum, floor 3, Solnavägen 9, Solna, starting at 2 pm and will also be broadcast digitally.

The program includes an update of Xbrane's long-term strategy, product portfolio, platform technology and an in-depth look at the imminent launch of Xlucane in Europe. Presentations will be made by Anders Tullgren, Chairman of the Board, Martin Åmark, CEO, David Vikström, Head of R&D, and Bryan Kim, Executive Vice President Global Specialty Pharmaceuticals, STADA Arzneimittel AG.

The program will also include a tour of Xbrane's new research lab at Campus Solna for those interested.

Please register your personal participation at: IR@xbrane.com and digital participation by following the link:
https://tv.streamfabriken.com/xbrane-biopharma-cmd-2022

Participants are welcome to ask questions at IR@xbrane.com or directly during the event.

Recordings of the presentations and presentation material will be available on the company's website, www.xbrane.com, the day after the event.

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com